In the entire Response letter, the FDA just indicated that deficiencies had been observed during the FDA’s facility inspection of Cadence’s third party manufacturer, which was finished on February 5, 2010.S. Release of generic AXERT tabletsMylan announces U.S. Launch of generic Fusilev for InjectionAlnylam presents positive ongoing phase 2 open-label extension data for Patisiran and RevusiranThe Company’s third party manufacturer intends to respond promptly to the observations, and Cadence plans to request a gathering with the FDA to make sure that the deficiencies have been adequately resolved to meet the requirements for NDA approval.SciFinder offers played a significant role in our research into the development of innovative, life-saving medicines, stated Steve Rees, VP, Screening Sample and Sciences Management at AstraZeneca. This partnership will support our worldwide R&D teams with the tools and knowledge they have to advance discoveries that will ultimately make a difference in the lives of individuals across the globe. An early on adopter of Enterprise-Wide Pricing, AstraZeneca offers relied on SciFinder to meet up the requirements of its experts for nearly a decade, and this five-year agreement is a first for SciFinder within the pharmaceutical sector.